PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
9124853-0	1996	Resistance to amikacin and isepamicin in rabbits with experimental endocarditis of an aac(6")-Ib-bearing strain of Klebsiella pneumoniae susceptible in vitro.	isepamicin	27-37	aminoglycoside N(6')-acetyltransferase	Klebsiella pneumoniae	86-96
9635511-3	1998	The animals given 300 mg/kg of isepamicin showed a significant increase in urine NAG (N-acetyl-beta-D-glucosaminidase) levels as compared with the control animals which received saline (p<0.01).	isepamicin	31-41	O-GlcNAcase	Rattus norvegicus	81-84
9635511-3	1998	The animals given 300 mg/kg of isepamicin showed a significant increase in urine NAG (N-acetyl-beta-D-glucosaminidase) levels as compared with the control animals which received saline (p<0.01).	isepamicin	31-41	O-GlcNAcase	Rattus norvegicus	86-117
9635511-4	1998	However, the increase in NAG level was markedly less when isepamicin was administered in combination with ceftriaxone (p<0.01).	isepamicin	58-68	O-GlcNAcase	Rattus norvegicus	25-28
9521682-1	1998	NMR spectroscopy, combined with molecular modeling, was used to determine the conformations of isepamicin and butirosin A in the active site of aminoglycoside 6"-N-acetyltransferase-Ii [AAC-(6")-Ii].	isepamicin	95-105	glycine-N-acyltransferase	Homo sapiens	186-189
9521682-5	1998	Conformer 2 of AAC(6")-Ii-bound isepamicin may represent an unproductive binding mode.	isepamicin	32-42	glycine-N-acyltransferase	Homo sapiens	15-18
9124853-1	1996	The effect of production of the aminoglycoside 6"-N-acetyltransferase [AAC(6")-IB] in Klebsiella pneumoniae on the outcome of amikacin and isepamicin treatment of rabbits with experimental endocarditis was assessed.	isepamicin	139-149	aminoglycoside N(6')-acetyltransferase	Klebsiella pneumoniae	71-81
8195610-5	1994	The activity of isepamicin was superior to that of amikacin against the TEM-3-AAC(6")-IV-producing strain.	isepamicin	16-26	aminoglycoside N(6')-acetyltransferase	Klebsiella pneumoniae	78-88
8622111-10	1995	The isepamicin plasma concentration curve following a 1 g intravenous dose to healthy volunteers can be best characterized by a tri-exponential curve corresponding to a t1/2 alpha of 0.17 h, a t1/2 beta of 2.1 h, and a gamma-phase of 34 h. The t1/2 beta represents the elimination phase and changes with age and renal functions, while the gamma-phase represents the return of drug to plasma from a deep compartment including binding in renal tissue.	isepamicin	4-14	interleukin 1 receptor like 1	Homo sapiens	244-253
8622108-21	1995	Because the principal resistance mechanism, (APH(2") + ACC(6"), confers high-level resistance to gentamicin and tobramycin and a lower level of resistance to amikacin, isepamicin and netilmicin, the observed resistance rate to netilmicin (15.0%) was the lowest for any of the aminoglycosides.	isepamicin	168-178	histocompatibility minor serpin domain containing	Homo sapiens	55-61
8622111-10	1995	The isepamicin plasma concentration curve following a 1 g intravenous dose to healthy volunteers can be best characterized by a tri-exponential curve corresponding to a t1/2 alpha of 0.17 h, a t1/2 beta of 2.1 h, and a gamma-phase of 34 h. The t1/2 beta represents the elimination phase and changes with age and renal functions, while the gamma-phase represents the return of drug to plasma from a deep compartment including binding in renal tissue.	isepamicin	4-14	CD6 molecule	Homo sapiens	169-189
8622111-10	1995	The isepamicin plasma concentration curve following a 1 g intravenous dose to healthy volunteers can be best characterized by a tri-exponential curve corresponding to a t1/2 alpha of 0.17 h, a t1/2 beta of 2.1 h, and a gamma-phase of 34 h. The t1/2 beta represents the elimination phase and changes with age and renal functions, while the gamma-phase represents the return of drug to plasma from a deep compartment including binding in renal tissue.	isepamicin	4-14	interleukin 1 receptor like 1	Homo sapiens	193-202
1804011-5	1991	The total body clearance (CLP) and renal clearance (CLR) of isepamicin significantly decreased as CLCR decreased.	isepamicin	60-70	chymotrypsin C	Homo sapiens	98-102
1449515-5	1992	Using a series of different aminoglycosides, we showed that molecules with a lower inhibitory potential (gentamicin B, amikacin and isepamicin) are surrounded by both hydrophobic and hydrophilic envelopes whereas aminoglycosides which are more inhibitory are enveloped primarily by either hydrophilic (kanamycin A or B) or hydrophobic (gentamicin C1a) envelopes.	isepamicin	132-142	endogenous retrovirus group K member 1	Homo sapiens	347-350
1804011-6	1991	The CLP of isepamicin and CLCR were significantly related [(COP = 0.391.	isepamicin	11-21	calmodulin like 3	Homo sapiens	4-7
10749517-8	2000	Isepamicin is not metabolised and is eliminated solely via the renal route with an elimination half-life (t 1/2 beta) of 2 to 3 hours in adults with normal renal function.	isepamicin	0-10	interleukin 1 receptor like 1	Homo sapiens	106-116
1804011-9	1991	Hemodialysis augmented the CLP of isepamicin by approximately 25-fold.	isepamicin	34-44	calmodulin like 3	Homo sapiens	27-30
16298874-6	2005	Isepamicin sulfate inhibited the enzyme activity (I(50) value, 2.1 mM; K(i) value, 1.7 mM), whereas thiamphenicol glisinat hydrochloride activated the G6PD dose dependently.	isepamicin	0-18	glucose-6-phosphate dehydrogenase	Rattus norvegicus	151-155
11995935-3	2002	However, the increase in NAG level was markedly less when isepamicin was administered in combination with fleroxacin (p<0.01).	isepamicin	58-68	O-GlcNAcase	Rattus norvegicus	25-28
11401545-14	2001	Furthermore, comparison of enzyme-bound conformations of isepamicin to the RNA-bound conformation of gentamycin C1a also showed remarkable similarities between the enzyme-bound and RNA-bound aminoglycoside antibiotic conformations.	isepamicin	57-67	endogenous retrovirus group K member 1	Homo sapiens	112-115
16440125-9	2006	The susceptible rates to amikacin and isepamicin were both 81.3% for ESBL-EC; 72.3% and 73.3% for ESBL-KP.	isepamicin	38-48	EsbL	Escherichia coli	69-73
16440125-9	2006	The susceptible rates to amikacin and isepamicin were both 81.3% for ESBL-EC; 72.3% and 73.3% for ESBL-KP.	isepamicin	38-48	EsbL	Escherichia coli	98-102